AptarGroup, Inc. 10-Q Summary: Quarter Ended September 30, 2008
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2008, for AptarGroup, Inc., a Delaware corporation. The company operates in the packaging components industry, developing and manufacturing consumer product dispensing systems. Operations are organized into three reportable segments: Beauty & Home (personal care, fragrance, household), Pharma (pharmaceutical dispensing), and Closures (dispensing closures). The company is a large accelerated filer with 67,511,022 shares of common stock outstanding as of October 21, 2008.
Key Financial Metrics
| Metric (in thousands) | Q3 2008 | Q3 2007 | 9 Months 2008 | 9 Months 2007 |
|---|---|---|---|---|
| Net Sales | $532,180 | $485,692 | $1,615,757 | $1,408,409 |
| Operating Income | $59,163 | $57,416 | $179,082 | $161,567 |
| Net Income | $39,651 | $39,395 | $121,825 | $105,943 |
| Diluted EPS | $0.57 | $0.56 | $1.72 | $1.48 |
| Operating Margin | 11.1% | 11.8% | 11.1% | 11.5% |
| Net Cash from Operations (9mo) | $203,161 (vs. $186,819 prior year) | |||
| Cash and Equivalents | $301,180 (Sep 30, 2008) | |||
| Total Debt (Short + Long Term) | $400,074 (Sep 30, 2008) |
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 10% in Q3 and 15% for the nine months ended September 30, 2008. Growth was driven by a 7-9% positive impact from foreign exchange rates (weaker U.S. dollar vs. Euro) and increased demand in the Pharma segment. Price increases in Closures and Beauty & Home segments offset rising input costs.
- Cost Pressures: Cost of sales as a percentage of net sales increased to 68.9% in Q3 2008 from 68.0% in Q3 2007. This was due to rising input costs (resin, tinplate, utilities), underutilized overhead in certain operations, and the translation impact of a weaker dollar on Euro-denominated costs.
- Segment Performance:
- Pharma: Sales grew 17% (Q3) and 21% (9 months), with segment income rising 17% and 27% respectively, driven by metered dose inhaler valves and nasal spray pumps.
- Beauty & Home: Sales grew 5% (Q3), but segment income declined 15% due to rising input costs and weakening demand in Europe.
- Closures: Sales grew 13% (Q3), with segment income flat (1% increase), offset by underutilized capacity and delayed price increases.
- Acquisitions: The company acquired Next Breath LLC (Pharma) and CCL Industries' Bag-on-Valve business (Beauty & Home) in early 2008. These were not material to the results of operations for the period.
Outlook, Risks, and Management Commentary
- Guidance: Management anticipates diluted earnings per share for the fourth quarter of 2008 to be in the range of $0.42 to $0.47, compared to $0.47 in the prior year.
- Market Conditions: The company expects weak demand in Beauty & Home and Closures segments due to the worldwide credit crisis and economic fears causing customers to delay orders. Conversely, strong Pharma sales are expected to continue.
- Currency Impact: The U.S. dollar strengthened at the end of Q3 relative to the Euro. If this trend continues, it will have a dilutive effect on the translation of results into U.S. dollars.
- Liquidity and Capital:
- Capital expenditures for 2008 are estimated at approximately $180 million.
- The company temporarily suspended its stock repurchase program to conserve cash due to the worldwide credit crisis, though it retains authorization to repurchase approximately 4.5 million additional shares.
- Net Debt to Net Capital ratio increased to 8% from 4% at year-end 2007.
- Risks: Key risks include fluctuations in foreign currency exchange rates, rising raw material costs (resin, metal), availability of raw materials, and the ability to pass cost increases to customers. The company also faces risks related to the implementation of a new worldwide ERP system in 2009.
Investor Verification Checklist
- Input Cost Pass-Through: Verify the company's ability to fully offset rising resin and metal costs with price increases in the Beauty & Home and Closures segments.
- Currency Hedging: Review the effectiveness of foreign exchange hedging strategies given the volatility between the U.S. dollar and the Euro.
- Pharma Demand Sustainability: Assess whether the strong growth in the Pharma segment (driven by allergy and asthma products) is sustainable into 2009.
- Capital Expenditure Timing: Monitor the $180 million capital expenditure plan, particularly the new ERP system implementation, for potential disruptions or cost overruns.
- Stock Repurchase Status: Confirm if the suspension of the stock repurchase program is lifted in the fourth quarter or if it extends into 2009.